Jeremy W. Cannon

Jeremy W. Cannon

Auto-generated profile, based on publicly available information

Jeremy W. Cannon

Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
JCJeremy W Cannon
Jeremy W Cannon
Understanding the pathophysiology of the body’s response to hemorrhage has led to improvements in prehospital care, more rapid hemostasis, avoidance of massive crystalloid resuscitation, and improved survival.

1 March 2017 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
JCJeremy W. Cannon
Jeremy W. Cannon
MKMansoor A. Khan
Mansoor A. Khan
ARAli S. Raja
Ali S. Raja
MCMitchell J. Cohen
Mitchell J. Cohen
JCJohn J. Como
John J. Como
JDJuan C. Duchesne
Juan C. Duchesne
The resuscitation of severely injured bleeding patients has evolved into a multi-modal strategy termed damage control resuscitation (DCR). This guideline evaluates several aspects of DCR including the role of massive transfusion (MT) protocols, the optimal target ratio of plasma (PLAS) and platelets (PLT) to red blood cells (RBC) during DCR, and the role of recombinant activated factor VII (rVIIa) and tranexamic acid (TXA). Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, a subcommittee of the Practice Management Guidelines (PMG) Section of EAST conducted a systematic review using MEDLINE and EMBASE. Articles in English from1985 through 2015 were considered in evaluating four PICO questions relevant to DCR. A total of 37 studies were identified for analysis, of which 31 met criteria for quantitative meta-analysis. In these studies, mortality decreased with use of an MT/DCR protocol vs. no protocol (OR 0.61, 95% CI 0.43-0.87, p = 0.006) and with a high ratio of PLAS:RBC and PLT:RBC (relatively more PLAS and PLT) vs. a low ratio (OR 0.60, 95% CI 0.46-0.77, p < 0.0001; OR 0.44, 95% CI 0.28-0.71, p = 0.0003). Mortality and blood product use were no different with either rVIIa vs. no rVIIa or with TXA vs. no TXA. DCR can significantly improve outcomes in severely injured bleeding patients. After a review of the best available evidence, we recommend the use of a MT/DCR protocol in hospitals that manage such patients and recommend that the protocol target a high ratio of PLAS and PLT to RBC. This is best achieved by transfusing equal amounts of RBC, PLAS, and PLT during the early, empiric phase of resuscitation. We cannot recommend for or against the use of rVIIa based on the available evidence. Finally, we conditionally recommend the in-hospital use of TXA early in the management of severely injured bleeding patients.

1 September 2016 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
JDJoseph J DuBose
Joseph J DuBose
TSThomas M Scalea
Thomas M Scalea
MBMegan Brenner
Megan Brenner
DSDimitra Skiada
Dimitra Skiada
KIKenji Inaba
Kenji Inaba
AGAAST AORTA Study Group
AAST AORTA Study Group
Aortic occlusion (AO) for resuscitation in traumatic shock remains controversial. Resuscitative endovascular balloon occlusion of the aorta (REBOA) offers an emerging alternative. The American Association for the Surgery of Trauma Aortic Occlusion for Resuscitation in Trauma and Acute Care Surgery registry prospectively identified trauma patients requiring AO from eight ACS Level 1 centers. Presentation, intervention, and outcome variables were collected and analyzed to compare REBOA and open AO. From November 2013 to February 2015, 114 AO patients were captured (REBOA, 46; open AO, 68); 80.7% were male, and 62.3% were blunt injured. Aortic occlusion occurred in the emergency department (73.7%) or the operating room (26.3%). Hemodynamic improvement after AO was observed in 62.3% [REBOA, 67.4%; open OA, 61.8%); 36.0% achieving stability (systolic blood pressure consistently >90 mm Hg, >5 minutes); REBOA, 22 of 46 (47.8%); open OA, 19 of 68 (27.9%); p =0.014]. Resuscitative endovascular balloon occlusion of the aorta (REBOA) access was femoral cut-down (50%); US guided (10.9%) and percutaneous without imaging (28.3%). Deployment was achieved in Zones I (78.6%), II (2.4%), and III (19.0%). A second AO attempt was required in 9.6% [REBOA, 2 of 46 (4.3%); open OA, 9 of 68 (13.2%)]. Complications of REBOA were uncommon (pseudoaneurysm, 2.1%; embolism, 4.3%; limb ischemia, 0%). There was no difference in time to successful AO between REBOA and open procedures (REBOA, 6.6 ± 5.6 minutes; open OA, 7.2 ± 15.1; p = 0.842). Overall survival was 21.1% (24 of 114), with no significant difference between REBOA and open AO with regard to mortality [REBOA, 28.2% (13 of 46); open OA, 16.1% (11 of 68); p = 0.120]. Resuscitative endovascular balloon occlusion of the aorta has emerged as a viable alternative to open AO in centers that have developed this capability. Further maturation of the American Association for the Surgery of Trauma Aortic Occlusion for Resuscitation in Trauma and Acute Care Surgery database is required to better elucidate optimal indications and outcomes. Therapeutic/care management study, level IV.

1 February 2016 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
JMJonathan Morrison
Jonathan Morrison
RGRichard E. Galgon
Richard E. Galgon
JJJan Olaf Jansen
Jan Olaf Jansen
JCJeremy W. Cannon
Jeremy W. Cannon
TRTodd Erik Rasmussen
Todd Erik Rasmussen
JEJonathan L. Eliason
Jonathan L. Eliason
Torso hemorrhage remains a leading cause of potentially preventable death within trauma, acute care, vascular, and obstetric practice. A proportion of patients exsanguinate before hemorrhage control. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is an adjunct designed to sustain the circulation until definitive hemostasis. A systematic review was conducted to characterize the current clinical use of REBOA and its effect on hemodynamic profile and mortality. A systematic review (1946-2015) was conducted using EMBASE and MEDLINE. Original studies on human subjects, published in English language journals, were considered. Articles were included if they reported data on hemodynamic profile and mortality. A total of 83 studies were identified; 41 met criteria for inclusion. Clinical settings included postpartum hemorrhage (5), upper gastrointestinal bleeding (3), pelvic surgery (8), trauma (15), and ruptured aortic aneurysm (10). Of the 857 patients, overall mortality was 423 (49.4%); shock was evident in 643 (75.0%). Pooled analysis demonstrated an increase in mean systolic pressure by 53 mm Hg (95% confidence interval, 44-61 mm Hg) following REBOA use. Data exhibited moderate heterogeneity with an I of 35.5. REBOA has been used in a variety of clinical settings to successfully elevate central blood pressure in the setting of shock. Overall, the evidence base is weak with no clear reduction in hemorrhage-related mortality demonstrated. Formal, prospective study is warranted to clarify the role of this adjunct in torso hemorrhage. Systematic review, level IV.

1 September 2011 in Surgery
Verified
Journal Article
Closed access
JWJoseph M. White
Joseph M. White
JCJeremy W. Cannon
Jeremy W. Cannon
ASAdam Stannard
Adam Stannard
NMNickolay P. Markov
Nickolay P. Markov
JSJerry R. Spencer
Jerry R. Spencer
TRTodd E. Rasmussen
Todd E. Rasmussen

31 May 2023 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
MRMason Remondelli
Mason Remondelli
KRKyle N. Remick
Kyle N. Remick
SSStacy A. Shackelford
Stacy A. Shackelford
JGJennifer M. Gurney
Jennifer M. Gurney
JPJeremy C. Pamplin
Jeremy C. Pamplin
DHDanielle B. Holt
Danielle B. Holt
As modern battlefield preparations have shifted towards a focus on conflict against peer and near-peer adversaries, large-scale combat operations (LSCO) present challenges to casualty care on a scale not experienced since World War II. Medical evacuation capabilities are anticipated to be episodic. Prolonged casualty care will require massive consumption of far-forward medical resources and healthcare personnel, however, likely without access to protected medical facilities. LSCO will generate mass casualty events (MCE) requiring methods for triage to provide medical care for the “greatest good.” Blood product availability will continue to be a critical life-saving intervention as well as a constraint in an operational environment without prolific damage control surgical capability. Past and present experiences with LSCO combined with predicted future LSCO scenarios will challenge the feasibility and effectiveness of massive casualty response, triage, evacuation, logistics, surgical damage control, and hospitalization which will likely require the integration of civilian surgeons and trauma systems. In this paper, we will analyze challenges and discuss potential solutions to combat casualty care in modern LSCO.